David R. Spigel MD

David Spigel, M.D., is a board-certified medical oncologist and the chief scientific officer at Sarah Cannon Research Institute. As chief scientific officer, Dr. Spigel oversees Sarah Cannon's clinical trial program, working with the research physician leaders and pharma/biotech partners to ensure cutting-edge therapies are available to patients.

Dr. Spigel is a board member of the Association of Community Cancer Centers and a member of the American Society of Clinical Oncology, the American Association of Cancer Research, the International Association for the Study of Lung Cancer, and the Lung Cancer Research Foundation.

Dr. Spigel's research has been published more than 150 times in peer-reviewed publications, including The Lancet Oncology, The New England Journal of Medicine, the Journal of Thoracic Oncology, the Journal of Oncology Practice, and the Journal of Clinical Oncology. He has served as an editor for several scientific publications, including Targeted Therapies, Oncology & Biotech News, Contemporary Oncology, and the World Journal of Clinical Oncology, and a reviewer for numerous other publications. Dr. Spigel has also presented at numerous scientific conferences.

Dr. Spigel earned his medical degree from the University of Tennessee College of Medicine. He then completed an internal medicine residency at Indiana University Medical Center, followed by a hematology/oncology fellowship at The Dana-Farber Cancer Institute in Boston.